Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Nl healthcare oct 10 - oct 16, 2015

137 views

Published on

Gyan research weekly newsletter on #healthcare sector

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this

Nl healthcare oct 10 - oct 16, 2015

  1. 1. Policy News  By FY2017, 3,000 Jan Aushadhi stores to open The Union Government will open at least 3,000 Jan Aushadhi stores by FY2017, of which 300 stores will be launched in the country by FY2016. This initiative is a part of Jan Aushadhi Scheme to supply quality and affordable generic medicines across India, mainly for the poor. The government has signed a memorandum of understanding (MoU) with a retail chain, CISSIL, to open 100 stores across Kerala by November 2015. As per the deal, CISSIL will provide the generic medicines from the stores in their super markets. Bureau of Pharma’s public sector undertakings would provide one-time assistance of INR 2.50 lakhs to set up a Jan Aushadhi outlet. Moreover in the next two months, around 184 Jan Aushadhi stores which are already operational in the country will supply at least 425 generic medicines. Industry News  Boehringer Ingelheim, Lupin to co-market Linagliptin in India Boehringer Ingelheim and Lupin have entered into a strategic agreement to co-market anti-diabetes drug Linagliptin - a novel Dipeptidylpeptidase-4 (DPP-4) inhibitor - in India. As per the contract, Lupin’s diabetes specialty field force will promote the drugs, marketed under new brand names - Ondero Met (fixed-dose combination with metformin) and Ondero (monotherapy). This initiative will not only expand the company’s diabetes portfolio, but also help it to consolidate its position as the fastest growing player in the top-5 anti-diabetes segment. Boehringer will carry out the sale of Linagliptin under the brand names Trajenta Duo (fixed-dose combination with metformin) and Trajenta (monotherapy) through its existing network and sales force. In India, the DPP-4 Inhibitors market is worth INR 1,499 crore and is growing at 26.55 percent. The anti-diabetic portfolio accounts for 15 percent of Lupin's India formulations sales.  Suven Life secures patent for neuro-degenerative drug Pharma company, Suven Life Sciences has secured patents from China, South Korea, Europe, Australia and the US for its neuro-degenerative drug. The patents from China and South Korea are valid until 2030, while patents from the rest of the regions are valid until 2031. Currently, the company has 22 granted patents from Australia, 17 from Europe, 19 from China, 23 from the US and 17 from South Korea. Suven has achieved these patents through its internal discovery research efforts. It patents in these markets are for new chemical entities for CNS therapy through mechanism of action - H3 Inverse. At various phases of clinical development, products developed from these inventions are likely to be out-licensed.  Roche Pharma rolls out new breast cancer drug Switzerland-based pharma company, Roche India has launched two new medicines - Perjeta and Kadcyla - to treat breast cancer. These drugs will increase survival and improve the quality of life for metastatic HER2-positive breast cancer patients. However, the pricing details of the two drugs were not declared. Roche’s breast cancer medicine, Herclon, has been available in India for several years. © Gyan Research and Analytics Pvt. Ltd., 2015 1 Healthcare News October 10, 2015 – October 16, 2015
  2. 2. © Gyan Research and Analytics Pvt. Ltd., 2015 2  PMDA plans to open India office Pharmaceuticals and Medical Devices Agency (PMDA), the drug regulator of Japan, plans to open an office in India to help Indian generic drug manufacturers who wanted to increase their presence in Japan either through export or partnering with Japanese companies. PMDA aims to lower healthcare costs by encouraging generic drugs, as the regulator is concerned about the ageing population and increasing healthcare costs in Japan, which are dominated by branded drugs. Currently, Japan’s healthcare market is about USD 110 billion. Japan aims to double the share of generics in its healthcare system by FY2018, in order to simplify the burden on public expenditure and transforming it into an attractive opportunity for Indian firms.  Aurobindo Pharma receives approval from USFDA for Alzheimer drug Aurobindo Pharma received the final approval for the Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (USFDA) to manufacture and sell Memantine Hydrochloride tablets of capacity 5 mg and 10 mg. These tablets are used in treatment of Alzheimer's disease. It is an extension of March 24, 2015 tentative approval. The approved tablet has a projected market size of USD 1.23 billion for the next 12 months which ends on August 2016. Aurobindo Pharma has a total of 215 ANDA approvals (188 final approvals including 10 from Aurolife Pharma LLC and 27 tentative approvals) from USFDA.  ICMR calls for tribal health research The Director General of Indian Council of Medical Research (ICMR) has pointed out the need for new research on tribal health in a collaborative effort by ICMR, government agencies and voluntary organizations. With fast changing living standards, tribals have become more vulnerable to non- communicable diseases. A central government research wing will undertake a research programme to outline programmes and policies for tribal health.  Reliance Life Sciences, Epirus terminates deal for Remicade Reliance Life Sciences has ended its deal with Boston-based Epirus Biopharmaceuticals to supply Remicade biosimilars. This drug is used to treat various diseases such as ulcerative colitis and rheumatoid arthritis. The move came as part of an internationally mediated dispute settlement between the two. Earlier, Epirus had tied up with Reliance for local supplies of the drug, manufactured by the latter at its site near Mumbai. However, thereafter Epirus entered into two separate contracts with Livzon MabPharm and Fujifilm Diosynth Biotechnologies for supplies of the same drug. Reliance alleged that Epirus had violated its exclusive global supply rights for the biosimilar drug - coded as BOW015. Healthcare News October 10, 2015 – October 16, 2015
  3. 3. © Gyan Research and Analytics Pvt. Ltd., 2015 3 Investment news  Apollo Hospitals to raise funds for expansion Apollo Hospitals Enterprise plans to raise up to INR 750 crore through a rights issue to fund the expansion of its healthcare business. Apollo will establish new hospitals in Bengaluru, Mumbai, Guwahati and Visakhapatnam. The company will investment INR 550 crore in Mumbai, INR 150 crore in Visakhapatnam and INR 170 crore in Bengaluru. The company's board had approved the rights issue in May and is awaiting regulatory approvals. Going forward, Apollo Health & Lifestyle Limited (AHLL) will also raise up to INR 500 crore through private equity partners for expansion. In India, AHLL operates a network of primary care as well as special care formats.  Mankind Pharma invested INR 150 crore in its Paonta Sahib plant Mankind Pharma has invested INR 150 crore in its Paonta Sahib plant and aims to launch 35 products by the end of 2016. The company is concentrating on nutraceuticals manufacturing at a growth rate of 35 percent. It is also focusing on the production of food supplements and beverages. Currently, the company's 80 percent of the niche molecules have been concentrated in the production of nutraceuticals and it has recently introduced 24 products under the segment. Healthcare News October 10, 2015 – October 16, 2015 Weekly Snapshot Market growth in the Indian Pharma Industry as on September 10, 2015 Type of market Market growth Gynecological 13.4 Respiratory 4.1 Pain and Analgesics 9 Anti-infectives 3.2 Gastronial 12.8 Anti-diabetic 18.1 Cardiac 11.8 Dermatologist 12.9 Urology 12.1 Source: AIOCD PharmaSoftech AWACS
  4. 4. © Gyan Research and Analytics Pvt. Ltd., 2015 4 Market Entry Strategies Market/ Marketing Research Pre-Feasibility, Feasibility & TEV Studies Equity Research & Valuation Economic Intelligence Our Business Practices Business Research Central Delivery Centre BD-9, Sector-1, Salt Lake City Kolkata - 700 064, India Phone: +91-33- 40060084 Corporate Office LG 37-38, Ansal Fortune Arcade, Sector - 18, Noida - 201 301 Delhi NCR, India Phone: +91-120- 2511945 E-mail: reports@gyananalytics.com Website: www.gyananalytics.com Branch Office - Mumbai Branch Office - Bangalore Branch Office - Hyderabad Healthcare News, October 10, 2015 – October 16, 2015

×